Research Article

Paeoniflorin Ameliorates Colonic Fibrosis in Rats with Postinfectious Irritable Bowel Syndrome by Inhibiting the Leptin/LepRb Pathway

Ya-Qing Tian,1 Sheng-Peng Zhang,1 Kun-Li Zhang,2 Di Cao,1 Yi-Jun Zheng,2 Ping Liu,2 Hui-Hui Zhou,1 Ya-Ning Wu,1 Qi-Xiang Xu,1 Xiao-Ping Liu,1 Xu-Dong Tang,1 Yong-Qiu Zheng1,2 and Feng-Yun Wang2

1Provincial Engineering Laboratory for Screening and Re-Evaluation of Active Compounds of Herbal Medicines in Southern Anhui, Teaching and Research Section of Traditional Chinese Medicine, School of Pharmacy, Wannan Medical College, Wuhu 241000, Anhui, China
2China Academy of Chinese Medical Sciences, Beijing, China

Correspondence should be addressed to Xu-Dong Tang; zhonw@vip.sina.com, Yong-Qiu Zheng; yongqiu.zheng@sina.com, and Feng-Yun Wang; wfy811@163.com

Received 19 May 2022; Accepted 1 August 2022; Published 3 October 2022

Academic Editor: Teh Lay Kek

Copyright © 2022 Ya-Qing Tian et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Postinfectious irritable bowel syndrome (PI-IBS) is a highly prevalent gastrointestinal disorder associated with immune dysregulation and depression- and anxiety-like behaviors. Through traditional medicine, the active ingredient of Paeoniae Radix called paeoniflorin (PF) was previously found to prevent the symptoms of PI-IBS. However, there is limited information on the effects of PF on intestinal function and depression- and anxiety-like symptoms in PI-IBS animal models. Here, we aimed to determine the effects of PF treatment on the symptoms of PI-IBS in a rat model. The PI-IBS rat model was established via early postnatal sibling deprivation (EPSD), trinitrobenzenesulfonic acid (TNBS), and chronic unpredictable mild stress (CUMS) stimulation and then treated with different dosages of PF (10, 20, and 40mg/kg) and leptin (1 and 10mg/kg). The fecal water content and body weight were measured to evaluate the intestinal function, while the two-bottle test for sucrose intake, open field test (OFT), and elevated plus maze test (EMT) were performed to assess behavioral changes. The serum leptin levels were also measured using an enzyme-linked immunosorbent assay. Furthermore, the expressions of leptin and its receptor, LepRb, were detected in colonic mucosal tissues through an immunohistochemical assay. The activation of the PI3K/AKT signaling pathway and the expression of brain-derived neurotrophic factor (BDNF) were also detected via western blotting. After the experimental period, the PI-IBS rats presented decreased body weight and increased fecal water content, which coincided with elevated leptin levels and heightened depression- and anxiety-like behaviors (e.g., low sucrose intake, less frequency in the center areas during OFT, and fewer activities in the open arms during EMT). However, the PF treatment ameliorated these observed symptoms. Furthermore, PF not only inhibited leptin/LepRb expression but also reduced the PI3K/AKT phosphorylation and BDNF expression in PI-IBS rats. Notably, cotreatment with leptin (10mg/kg) reduced the effects of PF (20mg/kg) on colonic fibrosis, leptin/LepRb expression, and PI3K/AKT activation. Therefore, our findings suggest that leptin is targeted by PF via the leptin/LepRb pathway, consequently ameliorating the symptoms of PI-IBS. Our study also contributes novel insights for elucidating the pharmacological action of PF on gastrointestinal disorders and may be used for the clinical treatment of PI-IBS in the future.

1. Introduction

In this modern age, the living habits and diets of humans are greatly influenced by the fast-paced and high-stress environment, contributing to chronic psychosocial disorders with high-risk factors for gastrointestinal diseases [1]. For example, postinfectious irritable bowel syndrome (PI-IBS) is described as a prevalent multifactorial disease with acute infectious enteritis accompanied by recurrent abdominal pain, altered bowel habits, fever, bellyache, vomiting,
diarrhea, gut flora, immune dysregulation, and depression-and anxiety-like disorders [2–4]. Currently, to manage these symptoms, different methods have been attempted, including probiotic intervention, moxibustion, psychotherapy, exercise, and antidepressant medication [5]. Although there are several drugs available for treating PI-IBS, effective and approved treatments for one or more of the symptoms of PI-IBS are still needed.

Previous studies reported that leptin might play an important role in the immune-mediated bowel dysfunction in IBS patients [6, 7]. Leptin is a 16 kDa nonglycosylated peptide hormone that exists in the rat intestine from the duodenum to the colon. The presence of a leptin receptor (LepRb) in the small intestine suggests that luminal leptin potentially modulates the immune system and gastrointestinal function [8, 9]. There is also evidence that leptin and LepRb participate in the pathogenesis of depression and anxiety [10, 11]. Additionally, previous studies reported that dextran sulfate sodium-induced trinitrobenzenesulfonic acid (TNBS) colitis is attenuated in mice with leptin deficiency [12, 13]. Further investigation confirmed that the plasma levels of leptin are significantly increased in the chronic unpredictable mild stress (CUMS) rat model [14]. Similarly, high serum levels of leptin are observed in patients with major depression [15]. Notably, infusing leptin into the murine ventral tegmental area could activate the leptin/LepRb downstream pathway and result in reduced anxiogenic behaviors [16]. Additionally, IBS patients display altered cytokine profiles, including the elevated circulating concentrations of the proinflammatory cytokine interleukin-6, which bears similarities in structural homology and intracellular signaling to leptin [6].

In fact, the therapeutic effects of medicines against PI-IBS are very hard to evaluate because of lacking preclinical animal models. TNBS was prepared by high-pressure sterilization, and the success rate of PI-IBS model establishment was more than 95% [17, 18]. However, PI-IBS is a common gastrointestinal disorder and is considered to be a functional disease because there appears to be no associated anatomical defect. Stress and psychological factors are thought to have an important role in IBS [19]. We develop a rat model of PI-IBS, not only with associated symptoms of immune-mediated bowel dysfunction of PI-IBS, such as recurrent abdominal pain, diarrhea, and gut flora but also with the pathogenesis of depression-and anxiety-like disorders. The model was established through complex stimulation with early postnatal sibling deprivation (EPSD), TNBS, and CUMS [20]. However, the exact role of leptin in a rat model with a gastrointestinal disorder, specifically induced via complex stimulation of EPSD, TNBS, and chronic unpredictable mild stress (CUMS), is unknown.

In traditional Chinese medicine, the roots of peony (Paeonia lactiflora Pall) are used for preparing various herbal formulas to treat depression, including “Danggui-Shaoyao-San” and “Xiaoyao powder” [21, 22]. Its main active component, called paeoniflorin (PF), a water-soluble monoterpenic glycoside, was discovered to exert remarkable anti-inflammatory, immunopharmacological, antidepressant, and antifibrotic effects in multiple animal models [23–25]. PF also has neuroprotective effects related to depression in animal models, such as CUMS [26, 27]. In addition, PF (30 mg/kg and 60 mg/kg) potentially exerts a neuroprotective effect against CUMS-induced hippocampal damage in rats by regulating the extracellular regulated protein kinase (ERK)-CAMP-response element binding protein (CREB) signaling pathway [24]. Furthermore, the herbal prescription Chang’an II, which also contains PF (paeoniflorin 38.35 mg/g), reportedly attenuates the symptoms of IBS at dosages of 2.85, 5.71, and 11.42 g/kg [28].

In the present study, we aimed to determine the effects of PF on intestinal function and depression- and anxiety-like behaviors in a PI-IBS animal model. Additionally, the effects of PF on the leptin/LepRb pathway were investigated in vivo.

2. Materials and Methods

2.1. Animals. Adult pregnant Sprague-Dawley rats (190–210 g) were purchased from Zhejiang Weitong Lihua Laboratory Animal Technology Co., Ltd. (animal license number SCXK; Zhejiang; 2019–0001). All rats were handled in accordance with the regulations of the National Institutes of Health, and the study was approved by the Institutional Animal Care and Use Committee of Wannan Medical College. Throughout the acclimatization and treatment periods, all animals had access to food and water ad libitum and were maintained on a 12 h light/dark cycle at 21 ± 2°C and 45 ± 10% relative humidity, except during the CUMS experiment and two-bottle test. The rats were also housed under specific pathogen-free conditions.

2.2. Establishment of the PI-IBS Rat Model. Since PI-IBS is an inflammatory immune disease, only newborn male rats were used. Based on previously published methods [28, 29], the rat model for PI-IBS was established using a multistimulation paradigm composed of EPSD, TNBS, and CUMS. Briefly, the litters were moved from the maternity cages to the adjacent cages at 9:00–12:00 AM during postnatal day 2 (PN2) to PN14. After pentobarbital anesthesia, colitis was induced in PN28 rats through intrarectal administration of 0.8 mL TNBS solution (20 mg per rat) in 50% ethanol, following a previously described method [30]. In contrast, the control rats were administered with 0.8 mL 50% ethanol as a vehicle. All solutions were delivered via a soft catheter and introduced 8 cm above the anus. After recovery from TNBS treatment for 2 weeks, the following procedures were performed: (1) water-fasting for 24 h; (2) fasting for 24 h; (3) reverse day/night cycle (dark from 7:00 to 19:00 and light from 19:00 to 7:00 the next day); (4) induction of cold stress for 5 min (the rats were placed in a transparent barrel containing ice water at 4°C at a depth of 15 cm); (5) induction of heat stress for 5 min (the rats were placed in a thermostat at 45°C); (6) pain induction (the rats were placed in an observation cage and their tails were clipped 1 cm from the distal tip, with appropriate strength to make the rat scream); (7) horizontal oscillation for 15 min (the rats were placed in a high-speed horizontal oscillator [110 r/min]). Each procedure was performed daily for 21 consecutive days (Figure 1) [31, 32].
2.3. Drug Treatment. Based on the previous study [24, 28], the dose of PF that we used in our PI-IBS models included the range of dosage (10, 20, and 40 mg/kg). We also allotted a 14-day pretreatment period to ensure sufficient time for the onset of PF activity. The PF (C23H28O11; MW: 480.45; purity: ≥95% [HPLC]; LD50: 9,530 mg/kg) obtained from Ningbo Dekang Biologic Product Co., Ltd. (Ningbo, China) was dissolved in distilled water and used for daily intra-gastric administration for 10–12 weeks. Recombinant rat leptin (R&D Systems, Minneapolis, MN, USA) was dissolved in sterile saline at a concentration of 1 mg/mL and intraperitoneally injected into the animals daily (at a dose of 1 and 10 mg/kg body weight) for 10–12 weeks. To determine the effective dosage of PF, the rats were randomly divided into five groups: (1) Normal, (2) PI-IBS, (3) PF (10 mg/kg) + PI-IBS, (4) PF (20 mg/kg) + PI-IBS, and (5) PF (40 mg/kg) + PI-IBS. To assess the effect of leptin on the mechanism of PF, the rats were randomly divided again into five groups: (1) Normal, (2) PI-IBS, (3) PF (20 mg/kg) + PI-IBS, (4) PF (20 mg/kg) + PI-IBS + leptin (1 mg/kg), and (5) PF (20 mg/kg) + PI-IBS + leptin (10 mg/kg).

2.4. Open Field Test (OFT). The rats were individually placed in the middle of an open field apparatus (height: 40.0 cm; length: 100.0 cm; width: 100.0 cm) between 8:00 and 11:00 AM. As described in a previous study [33], 25 squares (20.0 cm × 20.0 cm) were drawn on the floor, and the number of times that the rats crossed between squares was counted by two observers (blind to the experimental groups) over a 10 min period. Crossing squares, as a measure of locomotion, was counted when the rat had moved all four legs from one quadrant to another. After each trial, the open field apparatus was carefully cleaned.

2.5. Two-Bottle Test. To evaluate the effect of PF on depression, a two-bottle test for sucrose intake was performed as described in a previous study [34]. The rats were separately housed and supplied for 24 h with one bottle filled with tap water and another with 1% sucrose solution. To balance side preference, the locations of the two bottles were switched after 12 h. Following 24 h of fasting and water abstinence, the experimental process was immediately initiated after training completion. The rats were given 1 h of access to the two bottles, and the consumption in each bottle was recorded. The percentage of sucrose consumption was calculated as (sucrose intake/total intake) × 100%.

2.6. Elevated Plus Maze Test (EMT). Rats were placed at the intersection of a maze, consisting of two open and two closed arms, and left for 5 minutes. The 4 arms meet in a 5 cm × 5 cm central square open area which enabled the rats to freely enter each arm of the maze. Time spent in the open arms, number of times entering the open arms, and distance traveled in each arm by the rats were analyzed to evaluate anxiety-like behavior.

2.7. Histological Examination. One week after the two-bottle test, the rat colons were removed and fixed with paraformaldehyde. The colons were subsequently embedded in paraffin and cut into 5 μm-thick sections. For hematoxylin and eosin (H&E) and Masson trichrome staining, the slices were developed using 3,3’-diaminobenzidine (DAB) and then counterstained either with hematoxylin or using Tri-chrome, Gomori One-Step, Fast Green Stain Kit (Newcomer Supply, Middleton, WI, USA).

2.8. Immunohistochemical (IHC) Assay. The colon samples were fixed with 4% formalin and embedded in paraffin. Tissue slices (5 μm thick) were prepared for IHC staining. The leptin/LepRb antibody (1:200; Thermofisher Scientific, Waltham, MA, USA) was used as the primary antibody. With Image J software, we calculated the integrated optical density (IOD) of each section from 8 different 400x magnified fields. For IHC assessment, the entire tissue section was scanned and scored by two independent pathologists.

2.9. Measurement of Serum Leptin Levels. Venous blood samples (1 mL) were collected, centrifuged at 2,000 rpm for 10 min, and then stored at −80°C for temporary storage. The levels of leptin in the serum were measured using enzyme-linked immunosorbent assay (ELISA) kits, following the manufacturers’ protocols (Abcam, Cambridge, UK). The sample and standard dilutions were made using the experimental media.

2.10. Western Blot Analysis. Proteins were extracted from tissue samples or cell lysates using RIPA buffer (150 mM NaCl, 50 mM Tris-Cl, 1 mM EDTA, 1% w/v Triton X-100, 0.1% w/v SDS, and 1% w/v sodium deoxycholate; pH 8.0). To evaluate the effects of PF on leptin/LepRb downstream signaling, the PI-IBS rats were sacrificed, and colon homogenates were prepared. Protein concentrations were determined using a protein assay solution (Bio-Rad Laboratories, Hercules, CA, USA). Equivalent amounts of proteins were denatured in protein loading buffer, resolved on 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gels, and subsequently transferred to polyvinylidene difluoride (PVDF) membranes (Millipore, Billerica, MA, USA) via electroblotting. The PVDF membranes were blocked with 5% nonfat milk in Tris-buffered saline/Tween buffer for 1 h and incubated overnight at 4°C with the antibodies against phosphatidylinositol 3-kinase (PI3K, 1:1,000; Cell Signaling Technology, Danvers, MA, USA); p-PI3K (1:1,000; Cell Signaling Technology), protein kinase B (Akt, 1:1,000; Cell Signaling Technology), p-AKT (1:1,000; Cell Signaling Technology), brain-derived neurotrophic factor (BDNF, 1:1,000; Cell Signaling Technology), glyceraldehyde 3-phosphate dehydrogenase (GAPDH, 1:1,000; Cell Signaling Technology). The signals were detected using Pierce™ Electrochemiluminescence (ECL) Detection Reagent (Thermofisher Scientific), following the manufacturer’s protocol.
2.11. Statistical Analysis. The data obtained are presented as means ± SD. A significant difference was determined using a one-way analysis of variance (ANOVA), followed by Tukey’s test for multiple comparisons. A nonparametric test was used to compare the band density values between groups. Statistical significance was set at $P < 0.05$.

3. Results

3.1. Effects of PF Treatment on the Body Weight, Fecal Water Content, and Depression-and Anxiety-like Behaviors of PI-IBS Rats. To determine the effect of PF treatment in PI-IBS rats, the body weight and fecal pellets were first measured to assess the successful induction of the PI-IBS model. In addition, the two-bottle test, OFT and EMT were performed to observe the depression- and anxiety-like behaviors. After the EPSD, TNBS, and CUMS experiments, the rats exhibited lower body weight and higher fecal water content compared to the control rats, indicating the successful establishment of the PI-IBS model. Notably, compared to the PI-IBS group, the two PF + PI-IBS groups (20 and 40 mg/kg) showed a considerable increase in body weight and decreased fecal water content (Figures 2(a) and 2(b)). These results suggest that the symptoms in PI-IBS rats were alleviated after PF treatment. The results of the two-bottle test also determined the sucrose consumption in PI-IBS rats (Figure 2(c)). The ANOVA analysis revealed a significant decrease in sucrose preference after the EPSD, TNBS, and CUMS experiments. However, the preference for sucrose increased in PI-IBS rats after PF treatment, suggesting the PF-induced amelioration of PI-IBS symptoms (e.g., reduced intestinal function, depression). The ANOVA analysis also revealed the significant negative effects of the EPSD, TNBS, and CUMS experiments on the behavior of PI-IBS rats during OFT (Figure 3(a) and Table 1). However, the frequency of staying in the center areas increased in the PF + PI-IBS groups. Furthermore, there were no differences between the total distances crossed by the model and PF-treated groups. In the EMT, PF + PI-IBS rats and PI-IBS rats spent a similar amount of time in the open arms. The PI-IBS rats tended to spend more time, move more distance, and have more entries into the closed arms compared to the PF-treated rats (Figures 3(b)–3(d)). The results imply that the complex stimulation with early postnatal sibling deprivation (EPSD), TNBS, and CUMS caused the highest level of anxiety which was reduced by PF treatment.

3.2. Effects of PF Treatment on Colonic Inflammation and Fibrosis in PI-IBS Rats. The results of the histological examination showed that the active inflammation and chronic mucosal injury in PI-IBS rats were significantly more serious compared to those of the control. Further analysis using Masson’s trichrome staining revealed the excessive fibrotic remodeling in the submucosa and smooth muscle of PI-IBS rats. After PF treatment, examination of the colons from medium- (20 mg/kg) and high-dose (40 mg/kg) PF-treated rats revealed their normal appearance, but with less collagen in the submucosa and smooth muscle (Figures 4(a) and 4(b)), suggesting that the occurrence of fibroplasia was inhibited by PF. Overall, these results indicate that the protective effects of PF against PI-IBS injury produce long-term improvement in the intestinal structure and function in this immunoinflammatory rat model.

Since the PF treatment significantly inhibited the PI-IBS-induced inflammation and fibrosis, we further investigated leptin and LepRb, which can effectively inhibit PI-IBS in vivo, using IHC assay and ELISA to detect their expression levels in the rat intestine and serum. The IHC assay results demonstrated that leptin and LepRb expression levels were significantly increased after stimulation via EPSD, TNBS, and CUMS, which corroborated the high leptin content in the serum. Compared to PI-IBS rats, oral administration of PF (20 and 40 mg/kg) resulted in reduced leptin and LepRb expression in the colon and serum of PF + PI-IBS rats (Figures 5(a)–5(d)). Consequently, the activation of the leptin/LepRb downstream pathway, specifically the PI3K-AKT pathway, was significantly suppressed in the PF + PI-IBS groups. Furthermore, the PI-IBS-induced expression of BDNF was markedly reduced in the PF-treated groups compared to that in the PI-IBS model group (Figures 5(e) and 5(f)). These results strongly suggest that the regulation of leptin and LepRb expression, PI3K-AKT pathway activation, and BDNF expression are essential to the PF-induced recovery process in PI-IBS rats.

3.3. Administration of Leptin Reduces the Protective Effects of PF Treatment in PI-IBS Rats. To further explore the mechanism of PF via the leptin/LepRb pathway, additional experiments were performed to determine whether leptin and LepRb can be used as possible molecular targets for PF. The results showed that the cotreatment of leptin and PF could sufficiently inhibit the protective effects of PF in the PF + PI-IBS + leptin groups. In specific, colonic inflammation and fibrosis were aggravated to almost the same levels as that of model rats (nontreated) and coincided with increased fecal water content and decreased sucrose preference (Figure 6). Furthermore, compared to PI-IBS rats treated with
PF only, the PI-IBS rats treated with 10 mg/kg leptin and 20 mg/kg PF displayed higher leptin and LepRb expression levels, subsequently inducing the activation of the PI3K-AKT pathway. In contrast, the PI-IBS rats treated with 1 mg/kg leptin and 20 mg/kg PF exhibited features that were similar to those treated with PF only (Figure 7). These results imply that the leptin/LepRb signaling pathway is the direct inhibitory target of PF, resulting in the amelioration of PI-IBS symptoms, including excessive fibrotic remodeling in the submucosa and smooth muscle, chronic mucosal injury, reduced intestinal function, and depression- and anxiety-like behaviors.

**Figure 2:** PF treatment ameliorates the symptoms in PI-IBS rats. (a) Reduced fecal water content and suppressed body weight gain are observed in the experimental groups one day after CUMS and PF treatment. (b) No difference is observed between experimental groups one day before and after PF treatment. (c) Reduced sucrose consumption is observed between experimental groups one day before and after PF treatment. Data are presented as means ± SEM (n = 6 per group); *P < 0.05 and **P < 0.01 versus PI-IBS group.
4. Discussion

As the main active ingredient in peony [35], the pharmacological mechanisms of PF have been extensively studied in various inflammatory diseases, such as psoriasis, Parkinson’s disease, and rheumatoid arthritis [36–38]. In the present study, two novel findings were obtained: (1) the expression levels of leptin and LepRb were significantly elevated in the colon after EPSD, TNBS, and CUMS stimulation, and (2) the protective effects of PF in PI-IBS rats were related to the inhibition of the leptin/LepRb pathway.

As an important regulator during the pathogenesis of depression and inflammation, the circulating levels of leptin were found to be positively correlated with the severity of depression [39]. Additionally, Leptin can reportedly either promote or suppress inflammation in the intestines [40, 41]. Furthermore, elevated leptin and LepRb levels enhance fibrogenesis in the heart, liver, lungs, and other organs [42–44]. In the present study, we discovered that the expression levels of leptin and LepRb were significantly increased in the colon after EPSD, TNBS, and CUMS stimulation, which was consistent with the high leptin content in the serum, suggesting that leptin influences the development of colonic inflammation, fibrosis, and depression-like behavior in PI-IBS rats.

The PI-IBS model established through complex stimulation with EPSD, TNBS, and CUMS exhibits clinical symptoms that most closely match those of PI-IBS patients, such as interstitial cystitis, visceral hypersensitivity, and psychiatric disturbances, which were assessed in the present study. We then observed that PF treatment could improve the low body weight and high fecal water content in PI-IBS rats.
Table 1: Effects of PF on the behavior of rats in the open field test (n = 6).

| Group                  | Dose (mg.kg/d) | Total distance (cm)       | Distance in the center (cm) |
|------------------------|----------------|---------------------------|----------------------------|
| Normal                 | —              | 21825.18 ± 2398.25        | 1145.4 ± 292.27**          |
| PI-IBS                 | —              | 17456.94 ± 11374.55       | 316.72 ± 134.92           |
| PI-IBS + paeoniflorin  | 40             | 22618.44 ± 3154.50        | 645.16 ± 106.96**         |
| PI-IBS + paeoniflorin  | 20             | 18921.52 ± 2230.14        | 640.95 ± 25.29**          |
| PI-IBS + paeoniflorin  | 10             | 19698.85 ± 5617.20        | 771.52 ± 109.06**         |

Data were expressed as mean ± SD. **P < 0.01 versus the PI-IBS group.

Figure 4: (a) Histologic examination through H&E staining shows that PF treatment relieves the inflammatory infiltration in the colon of PI-IBS rats. Scale bar = 300 μm. (b) Masson’s trichrome staining demonstrates that PF treatment reduces fibrosis in the colon of PI-IBS rats. Scale bar = 100 μm. PF treatment Prevents Leptin/LepRb-mediated pathway activation in PI-IBS rats.
rats. Simultaneously, the PF treatment enhanced the preference for sucrose during the two-bottle test and the frequency in the center areas during the OFT and reduced the times, distance, and frequency of rats entering the closed arms during the EMT, indicating that PF ameliorated the depression- and anxiety-like behaviors in PI-IBS rats. The results of the histological examination confirmed that PF exerted anti-inflammatory and antifibrotic effects on PI-IBS rats. Moreover, the PF treatment was found to alleviate the inflammation, fibrosis, and depression-like behavior in PI-IBS rats by downregulating the leptin and LepRb expression in the colon and serum. Notably, further investigation

Figure 5: PF treatment inhibits the leptin/LepRb pathway activation in PI-IBS rats. ((a)-(b)) Evaluation of leptin (a) and LepRb (b) expression in the colon tissues via IHC staining. Scale bar = 300 μm. (c) IOD value of leptin and LepRb. (d) Analysis of the leptin serum levels using an ELISA kit shows the reduced leptin serum levels after PF administration (20 and 40 mg/kg). (e)-(f) Western blot analysis of p-PI3K/PI3K, p-AKT/AKT, and BDNF/GAPDH protein expression. (e) Representative gel images of p-PI3K, PI3K, p-AKT, AKT, and BDNF, with GAPDH as control. (f) The bar graph shows the quantitative evaluation of p-PI3K/PI3K, p-AKT/AKT, and BDNF/GAPDH expression (n = 3). *P < 0.05 and **P < 0.01 versus PI-IBS group.
revealed that the protective effects of PF on PI-IBS rats were fully reversed after cotreatment with 10 mg/kg leptin. Thus, our findings demonstrate that the protective effects of PF on PI-IBS rats are directly related to the inhibition of the leptin/LepRβ pathway.

Previous studies reported that the binding of leptin to LepRβ resulted in the suppression of the glycogen synthase kinase 3β (GSK3β)/β-catenin signaling, which was characterized by the increased phosphorylation of PI3K and AKT and expression of BDNF [45–47]. Hence, we also attempted to determine the role of the leptin-mediated PI3K/AKT pathway in the PI-IBS rat model. The PI3K/AKT pathway is essential for the maintenance of intestinal function and for regulating a variety of important biological processes [48, 49]. As a key molecule, PI3K was also found to participate in intestinal inflammation and fibrosis [50, 51]. The activation of PI3K is known to enhance the phosphorylation of AKT and to negatively regulate the activity of GSK3β [52]. Similarly, we observed that the administration of PF inhibited the activation of the leptin/LepRβ-mediated PI3K/AKT pathway in PI-IBS rats, which was associated with reduced depression- and anxiety-like behaviors, suggesting that PF ameliorates the symptoms in PI-IBS rats by suppressing the leptin/LepRβ downstream pathway.

In addition, BDNF is reported to exist in the intestinal mucosa and enteric nervous system, which are modulated by the PI3K/AKT/GSK3β pathway. Interestingly, BDNF is a neuromodulator associated with the clinical features of IBS, such as abdominal pain and discomfort [53–57]. Furthermore, TNBS-induced colon inflammation is associated with high BDNF expression and the stimulation of sensory neurons in the dorsal root ganglia [58]. In the present study, the oral administration of PF inhibited the BDNF expression in the colon of PI-IBS rats. However, treatment with leptin (10 mg/kg) reversed the effects of PF on BDNF expression, demonstrating that PF ameliorates the PI-IBS symptoms by suppressing the BDNF expression in the colon.

Thus, the leptin/LepRβ pathway may be associated with the multifactorial effects of PF against gastrointestinal disorders and depression- and anxiety-like behaviors in PI-IBS

**Figure 6:** Leptin treatment reduces the anti-inflammatory and antifibrotic effects of PF on PI-IBS rats. (a) Representative images of H&E-stained colon tissues show the degree of inflammation. Scale bar = 300 μm. (b) Masson’s trichrome-stained colon tissues show the degree of fibrosis. Scale bar = 100 μm. (c) Sucrose consumption between experimental groups one day before and after PF treatment. (d) Fecal water content between experimental groups one day before and after PF + leptin treatment. **P < 0.01 versus PI-IBS group; *P < 0.05 and ##P < 0.01 versus PI-IBS + PF (20 mg/kg) group.**
Figure 7: Leptin administration attenuates the effects of PF by inhibiting the activation of leptin/LepRb downstream signaling. (a)-(b) Evaluation of leptin (a) and LepRb (b) expression in the colon tissues via IHC staining. Scale bar = 300 μm. (c) IOD value of leptin and LepRb. (d)-(e) Western blot analysis of p-PI3K/PI3K, p-AKT/AKT, and BDNF/GAPDH protein expression. (d) Representative gel images of p-PI3K, PI3K, p-AKT, AKT, and BDNF, with GAPDH as control. (e) Bar graph showing the quantitative evaluation of p-PI3K/PI3K, p-AKT/AKT, and BDNF/GAPDH expression (n = 3). *P < 0.05 and **P < 0.01 versus PI-IBS group; ##P < 0.05 versus PI-IBS + PF (20 mg/kg) group.
rats. However, further research is required to fully elucidate the association between PF, leptin, and PI-IBS. In summary, leptin has been confirmed as the target of PF in ameliorating the symptoms in PI-IBS rats, such as excessive fibrotic remodeling in the submucosa and depression- and anxiety-like behaviors via the inhibited activation of the leptin/LepRb downstream pathway—the PI3K/AKT pathway. Taken together, our findings implicate leptin/LepRb as an important target of PF and identify it as a potential biomarker for human patients with gastrointestinal disorders.

5. Conclusion

Therefore, we hypothesize that PF ameliorates the symptoms in PI-IBS rats by suppressing the leptin/LepRb downstream pathway.

Data Availability

No data were used in this study.

Disclosure

This manuscript has been presented as “pre-print” in “research square” according to the following link: https://www.researchsquare.com/article/rs-1269042/v1, and then a reference to the preprint was included in the reference list of the manuscript [59].

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

Y-Q Z designed the study, performed the experiments, analyzed the data, and wrote the manuscript. Y-J Z, Y-N W, and DC performed the experiments and wrote the manuscript. HZ, X-D T, Y-Q T, PL, Q-X X, and KZ performed the experiments. S-P Z, X-P L, and F-Y W conceptualized the study and edited the manuscript. All authors have read, reviewed, and approved the submitted version. Ya-Qing Tian, Sheng-Peng Zhang, and Kun-Li Zhang contributed equally to this work.

Acknowledgments

The authors would like to thank Editage (https://www.editage.cn) for English language editing. This study was supported by financial grants from the Major Science and Technology Project for “Significant New Drugs Creation” (Grant No. 2019ZX09201005-003), University Collaborative Innovation Project of Anhui (Grant No. GXXT-2020-024), and Talent Funding Projects of the https://doi.org/10.13039/501100014980Wannan Medical College (Grant No. WYRCQD2018009).

References

[1] L. Wei, Y. Li, and W. Tang, “Chronic unpredictable mild stress in rats induces colonic inflammation,” Frontiers in Physiology, vol. 10, p. 1228, 2019.
[2] Z. Gong, Y. Chen, and R. Zhang, “Pharmacokinetics of two alkaloids after oral administration of rhizoma coptidis extract in normal rats and irritative bowel syndrome rats,” Evidence Based Complementary and Alternative Medicine, vol. 2014, Article ID 845048, 2014.
[3] C. J. Black and A. C. Ford, “Global burden of irritable bowel syndrome: trends, predictions and risk factors,” Nature Reviews Gastroenterology & Hepatology, vol. 17, no. 8, pp. 473–486, 2020.
[4] Y. Y. Shao, Y. Guo, X. J. Feng et al., “Oridonin attenuates TNBS-induced post-inflammatory irritative bowel syndrome via PXR/NF-κB signaling,” Inflammation, vol. 44, no. 2, pp. 645–658, 2021.
[5] C. Carco, W. Young, R. B. Gearly, N. J. Talley, W. C. McNabb, and N. C. Roy, “Increasing evidence that irritable bowel syndrome and functional gastrointestinal disorders have a microbial pathogenesis,” Frontiers in Cellular and Infection Microbiology, vol. 10, p. 468, 2020.
[6] M. M. Buckley, R. O’Brien, M. Devlin et al., “Leptin modifies the prosecretory and prokinetic effects of the inflammatory cytokine interleukin-6 on colonic function in Sprague-Dawley rats,” Experimental Physiology, vol. 101, no. 12, pp. 1477–1491, 2016.
[7] K. R. Weaver, C. M. Boulineaux, J. M. Robinson, K. Butler, M. M. Heitkemper, and W. A. Henderson, “Sex hormones, BDNF, leptin, and ‘TGF-β1 in females with IBS: a pilot investigation,” Biological Research For Nursing, vol. 23, no. 2, pp. 231–237, 2021.
[8] S. Sitaraman, X. Liu, L. Charrier et al., “Colonic Leptin: source of a novel pro-inflammatory cytokine involved in inflammatory bowel disease,” The FASEB Journal, vol. 18, no. 6, pp. 696–698, 2004.
[9] D.-R. Liu, X.-J. Xu, and S.-K. Yao, “Increased intestinal mucosal leptin levels in patients with diarrhea-predominant irritable bowel syndrome,” World Journal of Gastroenterology, vol. 24, no. 1, pp. 46–57, 2018.
[10] W. Liu, J. Liu, J. Xia et al., “Leptin receptor knockout-induced depression-like behaviors and attenuated antidepressant effects of exercise are associated with STAT3/SOC33 signaling,” Brain, Behavior, and Immunity, vol. 61, pp. 297–305, 2017.
[11] M. F. Fernandes, D. Lau, S. Sharma, and S. Fulton, “Anxiety-like behavior in female mice is modulated by STAT3 signaling in midbrain dopamine neurons,” Brain, Behavior, and Immunity, vol. 95, pp. 391–400, 2021.
[12] B. Siegmund, H. A. Lehr, and G. Fantuzzi, “Leptin: a pivotal mediator of intestinal inflammation in mice,” Gastroenterology, vol. 122, no. 7, pp. 2011–2025, 2002.
[13] B. Rivero-Gutiérrez, M. Arredondo-Amador, R. Gámez-Belmonte, F. Sánchez de Medina, and O. Martínez-Augustin, “Leptin-resistant Zucker rats with trinitrobenzene sulfonic acid colitis present a reduced inflammatory response but enhanced epithelial damage,” American Journal of Physiology—Gastrointestinal and Liver Physiology, vol. 321, no. 2, pp. G157–g170, 2021.
[14] J. L. Yang, D. X. Liu, H. Jiang, F. Pan, C. S. Ho, and R. C. Ho, “The effects of high-fat-diet combined with chronic unpredictable mild stress on depression-like behavior and leptin/LepRb in male rats,” Scientific Reports, vol. 6, no. 1, p. 35239, 2016.
[15] Y. Milaneschi, F. Lamers, M. Bot, M. L. Drent, and B. W. Penninx, "Leptin dysregulation is specifically associated with major depression with atypical features: evidence for a mechanism connecting obesity and depression," *Biological Psychiatry*, vol. 81, no. 9, pp. 807–814, 2017.

[16] J. Liu, M. Guo, and X. Y. Lu, "Leptin/LepRb in the ventral tegmental area mediates anxiety-related behaviors," *International Journal of Neuropsychopharmacology*, vol. 19, no. 2, 2016.

[17] A. Bensoussan, N. J. Talley, M. Hing, R. Menzies, A. Guo, and M. Ngu, "Treatment of irritable bowel syndrome with Chinese herbal medicine: a randomized controlled trial," *JAMA*, vol. 280, no. 18, pp. 1585–1589, 1998.

[18] L. J. Brandt, L. J. Brandt, and W. D. Chey, "An evidence-based position statement on the management of irritable bowel syndrome," *American Journal of Gastroenterology*, vol. 104, pp. S1–S35, 2009.

[19] L. Saha, "Irritable bowel syndrome: pathogenesis, diagnosis, treatment, and evidence-based medicine," *World Journal of Gastroenterology*, vol. 20, no. 22, pp. 6759–6973, 2014.

[20] H. H. Zhou, Y. M. Zhang, S. P. Zhang et al., "Suppression of PTPRf alleviates post-infectious irritable bowel syndrome via downregulation of the TLR4 pathway in rats," *Frontiers in Pharmacology*, vol. 12, Article ID 724410, 2021.

[21] Z. Huang, Q. Q. Mao, X. M. Zhong, Z. Y. Li, F. M. Qiu, and S. P. Ip, "Mechanistic study on the antidepressant-like effect of danggui-shaoyao-san, a Chinese herbal formula," *Evidence Based Complementary and Alternative Medicine*, vol. 2012, Article ID 173565, 2012.

[22] X. Wang, X. Ye, X. Liu, J. Luo, N. Zeng, and R. Liu, "Research status of antidepressant effect of Xiaoyaoxian", *Chinese Journal of Experimental Traditional Medical Formulae*, vol. 24, no. 16, pp. 212–220.

[23] Y. Q. Zheng and W. Wei, "Total glucosides of paeony suppress adjuvant arthritis in rats and intervenes cytokine-signaling between different types of synovocytes," *International Immunopharmacology*, vol. 5, no. 10, pp. 1560–1573, 2005.

[24] X. Zhong, G. Li, F. Qiu, and Z. Huang, "Paeonol and paeoniflorin ameliorate chronic stress-induced depression-like behaviors and neuronal damages in rats via activation of the ERK-CREB pathway," *Frontiers in Psychiatry*, vol. 9, p. 772, 2018.

[25] X. Ma, W. Zhang, Y. Jiang, J. Wen, S. Wei, and Y. Zhao, "Paeonol and paeoniflorin, a natural product with multiple targets in liver diseases-a mini review," *Frontiers in Pharmacology*, vol. 11, p. 531, 2020.

[26] S. Z. Zhong, Q. H. Ge, Q. Li, R. Qu, and S. P. Ma, "Paeonol and paeoniflorin attenuates Abeta ((1–42))-mediated neurotoxicity by regulating calcium homeostasis and ameliorating oxidative stress in hippocampus of rats," *Journal of Neurological Sciences*, vol. 280, no. 1-2, pp. 71–78, 2009.

[27] Q. Q. Mao, X. M. Zhong, C. R. Feng, A. J. Pan, Z. Y. Li, and Z. Huang, "Protective effects of paeonol against glutamate-induced neurotoxicity in PC12 cells via antioxidant mechanisms and Ca(2+)- antagonism," *Cellular and Molecular Neurobiology*, vol. 30, no. 7, pp. 1059–1066, 2010.

[28] F. Y. Wang, M. Su, Y. Q. Zheng et al., "Herbal prescription Chang'an II repairs intestinal mucosal barrier in rats with post-inflammation irritable bowel syndrome," *Acta Pharmacologica Sinica*, vol. 36, no. 6, pp. 708–715, 2015.

[29] X. Ma, X. Wang, and N. Kang, "The effect of Tong-Xie-Yao-Fang on intestinal mucosal mast cells in post-inflammatory irritable bowel syndrome rats," *Evidence Based Complementary and Alternative Medicine*, vol. 2017, Article ID 9086034, 2017.

[30] H.-Y. Qin, H.-T. Xiao, J. C. Wu, B. M. Berman, J. J. Sung, and Z.-X. J. W. J. o.G. W. B. W. B. W. B., "Key factors in developing the trinitrobenzene sulfonic acid-induced post-inflammatory irritable bowel syndrome model in rats," *World Journal of Gastroenterology*, vol. 18, no. 20, p. 2481, 2012.

[31] E. Isingrini, V. Camus, A.-M. Le Guisquet, M. Pingaud, S. Devers, and C. J. P. O. Belzung, "Association between repeated unpredictable chronic mild stress (UCMS) procedures with a high fat diet: a model of fluoxetine resistance in mice," *PLoS One*, vol. 5, no. 4, Article ID e10404, 2010.

[32] Y. S. Mineur, C. Belzung, and W. E. J. B. R. Crusio, "Effects of unpredictable chronic mild stress on anxiety and depression-like behaviour in mice," *Behavioural Brain Research*, vol. 175, no. 1, pp. 43–50, 2006.

[33] X. Geng, H. Wu, Z. Li et al., "Jie-Yu-Huan capsule ameliorates anxiety-like behaviours in rats exposed to chronic restraint stress via the cAMP/PKA/CREB/BDNF signalling pathway," *Oxidative Medicine and Cellular Longevity*, vol. 2021, Article ID 1703981, 2021.

[34] A. Ribeiro-Carvalho, C. S. Lima, A. L. Nunes-Freitas, C. C. Filgueiras, A. C. Manhães, and Y. J. B. B. Abreu-Villaça, "Exposure to nicotine and ethanol in adolescent mice: effects on depressive-like behavior during exposure and withdrawal," *Behavioural Brain Research*, vol. 221, no. 1, pp. 282–289, 2011.

[35] X. Z. Yang and W. Wei, "CP-25, a compound derived from paeonol: research advance on its pharmacological actions and mechanisms in the treatment of inflammation and immune diseases," *Acta Pharmacologica Sinica*, vol. 41, no. 11, pp. 1387–1394, 2020.

[36] W. Du, X. Liang, S. Wang, P. Lee, and Y. Zhang, "The underling mechanism of paeonia lactiflora Pall. in Parkinson's disease based on a network pharmacology approach," *Frontiers in Pharmacology*, vol. 11, Article ID 581984, 2020.

[37] L. Zhang and W. Wei, "Anti-inflammatory and immunoregulatory effects of paeonol and total glucosides of paeony," *Pharmaco-therapy & Therapeutics*, vol. 207, Article ID 107452, 2020.

[38] J. Wen, B. Xu, Y. Sun et al., "Paeonol and paeoniflorin protects against intestinal ischemia/reperfusion by activating LKB1/AMPK and promoting autophagy," *Pharmacological Research*, vol. 146, Article ID 104308, 2019.

[39] T. Ge, J. Fan, W. Yang, R. Cui, and B. Li, "Leptin in depression: a potential therapeutic target," *Cell Death & Disease*, vol. 9, no. 11, p. 1096, 2018.

[40] B. Rivero-Gutiérrez, C. J. Aranda, B. Ocón, M. Arredondo, O. Martínez-Augustín, and F. Sánchez de Medina, "Exogenous Leptin reinforces intestinal barrier function and protects from colitis," *Pharmacological Research*, vol. 147, Article ID 104356, 2019.

[41] J. F. Ziegler, C. Böttcher, M. Letizia et al., "Leptin induces TNFα-dependent inflammation in acquired generalized lipodystrophy and combined Crohn's disease," *Nature Communications*, vol. 10, no. 1, p. 5629, 2019.

[42] S. Zhao, N. Li, Y. Zhu et al., "Partial leptin deficiency confers resistance to diet-induced obesity in mice," *Molecular Metabolism*, vol. 37, Article ID 100995, 2020.

[43] R. Gogiraju, A. Hubert, J. Fahrer et al., "Endothelial leptin receptor deletion promotes cardiac autophagy and angiogenesis following pressure overload by suppressing akt/mTOR signaling," *Circulation Heart Failure*, vol. 12, no. 1, Article ID e005622, 2019.

[44] H. Han, S. I. Chung, H. J. Park et al., "Obesity-induced vitamin D deficiency contributes to lung fibrosis and airway hyperresponsiveness," *American Journal of Respiratory Cell and Molecular Biology*, vol. 64, no. 3, pp. 357–367, 2021.
[45] J. C. Garza, M. Guo, W. Zhang, and X. Y. Lu, "Leptin restores adult hippocampal neurogenesis in a chronic unpredictable stress model of depression and reverses glucocorticoid-induced inhibition of GSK-3β/β-catenin signaling," *Molecular Psychiatry*, vol. 17, no. 8, pp. 790–808, 2012.

[46] X. Zhu, X. Jia, F. Cheng, H. Tian, and Y. Zhou, "c-Jun acts downstream of PI3K/AKT signaling to mediate the effect of Leptin on methionine adenosyltransferase 2B in hepatic stellate cells in vitro and in vivo," *The Journal of Pathology*, vol. 252, no. 4, pp. 423–432, 2020.

[47] B. Qian, Y. Yang, N. Tang et al., "M1 macrophage-derived exosomes impair beta cell insulin secretion via miR-212-5p by targeting SIRT2 and inhibiting Akt/GSK-3β/β-catenin pathway in mice," *Diabetologia*, vol. 64, no. 9, pp. 2037–2051, 2021.

[48] R. A. Irizarry-Caro, M. M. McDaniel, G. R. Overcast, V. G. Jain, T. D. Troutman, and C. Pasare, "TLR signaling adapter BCAP regulates inflammatory to reparatory macrophage transition by promoting histone lactylation," *Proceedings of the National Academy of Sciences*, vol. 117, no. 48, pp. 30628–30638, 2020.

[49] S. J. Zhao, F. Q. Kong, J. Jie et al., "Macrophage MSR1 promotes BMSC osteogenic differentiation and M2-like polarization by activating PI3K/AKT/GSK3β/β-catenin pathway," *Theranostics*, vol. 10, no. 1, pp. 17–35, 2020.

[50] Y. Mishima, A. Oka, B. Liu et al., "Microbiota maintain colonic homeostasis by activating TLR2/MyD88/PI3K signaling in IL-10-producing regulatory B cells," *Journal of Clinical Investigation*, vol. 129, no. 9, pp. 3702–3716, 2019.

[51] Y. Lo, J. P. Sauve, S. C. Menzies, T. S. Steiner, and L. M. Sly, "Phosphatidylinositol 3-kinase p110δ drives intestinal fibrosis in SHIP deficiency," *Mucosal Immunology*, vol. 12, no. 5, pp. 1187–1200, 2019.

[52] C. Chen, F. Zhou, L. Zeng, Z. Jiang, and Z. Hu, "Methylene blue offers neuroprotection after intracerebral hemorrhage in rats through the PI3K/Akt/GSK3β signaling pathway," *Journal of Cellular Physiology*, vol. 234, no. 4, pp. 5304–5318, 2019.

[53] Y. B. Yu, X. L. Zuo, Q. J. Zhao et al., "Brain-derived neurotrophic factor contributes to abdominal pain in irritable bowel syndrome," *Gut*, vol. 61, no. 5, pp. 685–694, 2012.

[54] L. Huang, J. Jin, K. Chen et al., "BDNF produced by cerebral microglia promotes cortical plasticity and pain hypersensitivity after peripheral nerve injury," *PLoS Biology*, vol. 19, no. 7, Article ID e3001337, 2021.

[55] M. Liu, J. C. Kay, S. Shen, and L. Y. Qiao, "Endogenous BDNF augments NMDA receptor phosphorylation in the spinal cord via PLCγ, PKC, and PI3K/Akt pathways during colitis," *Journal of Neuroinflammation*, vol. 12, no. 1, p. 151, 2015.

[56] M. Y. Chien, C. H. Chuang, C. M. Chern et al., "Salvianolic acid A alleviates ischemic brain injury through the inhibition of inflammation and apoptosis and the promotion of neurogenesis in mice," *Free Radical Biology and Medicine*, vol. 99, pp. 508–519, 2016.

[57] F. Xue, Z. Zhao, Y. Gu, J. Han, K. Ye, and Y. Zhang, "7, 8-Dihydroxyflavone modulates bone formation and resorption and ameliorates ovariectomy-induced osteoporosis," *Elife*, vol. 10, Article ID e64872, 2021.

[58] C. M. Xia, M. A. Gullick, S. J. Yu et al., "Up-regulation of brain-derived neurotrophic factor in primary afferent pathway regulates colon-to-bladder cross-sensitization in rat," *Journal of Neuroinflammation*, vol. 9, no. 1, p. 30, 2012.

[59] D. Cao, Y. Wu, and K. Zhang, "Paeoniflorin ameliorates colonic fibrosis in rats with postinfectious irritable bowel syndrome by inhibiting the leptin/leprb pathway," 2022.